[{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"SipNose","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Noveome Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Noveome Biotherapeutics"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Noveome Biotherapeutics \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"Noveome Biotherapeutics \/ Parexel"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"U.S. Navy Bureau of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ U.S. Navy Bureau of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ U.S. Navy Bureau of Medicine"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Walter Reed Army Institute","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"ST266","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Walter Reed Army Institute","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Walter Reed Army Institute"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Singota Solutions","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"ST266","moa":"AChE","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Noveome Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Noveome Biotherapeutics"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Commonwealth Of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"ST266","moa":"AChE","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Commonwealth Of Pennsylvania","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Commonwealth Of Pennsylvania"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Amnion-Derived Cellular Cytokine","moa":"Cytokine","graph1":"Dental and Oral Health","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Noveome Biotherapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
